Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Aging | 111 | 2023 | 1630 | 11.620 |
Why?
|
Cognition | 72 | 2023 | 1314 | 9.500 |
Why?
|
Health Literacy | 19 | 2023 | 105 | 9.080 |
Why?
|
Alzheimer Disease | 79 | 2023 | 2005 | 8.710 |
Why?
|
Cognitive Dysfunction | 51 | 2023 | 969 | 8.050 |
Why?
|
Decision Making | 21 | 2023 | 227 | 7.670 |
Why?
|
Cognition Disorders | 59 | 2019 | 1032 | 6.470 |
Why?
|
Aged, 80 and over | 185 | 2023 | 4930 | 6.410 |
Why?
|
Aged | 217 | 2023 | 9620 | 5.820 |
Why?
|
Brain | 63 | 2023 | 1726 | 5.770 |
Why?
|
Independent Living | 18 | 2023 | 285 | 5.280 |
Why?
|
Dementia | 30 | 2021 | 527 | 4.470 |
Why?
|
Longitudinal Studies | 77 | 2023 | 1462 | 4.430 |
Why?
|
Neuropsychological Tests | 80 | 2022 | 1270 | 4.260 |
Why?
|
Female | 215 | 2023 | 16412 | 4.190 |
Why?
|
Male | 215 | 2023 | 15851 | 4.150 |
Why?
|
Humans | 268 | 2023 | 29814 | 3.900 |
Why?
|
Cohort Studies | 81 | 2023 | 1952 | 3.310 |
Why?
|
Cerebral Amyloid Angiopathy | 7 | 2023 | 118 | 2.440 |
Why?
|
Delivery of Health Care | 7 | 2023 | 156 | 2.390 |
Why?
|
Neurodegenerative Diseases | 7 | 2021 | 117 | 2.300 |
Why?
|
Cognitive Aging | 5 | 2021 | 81 | 2.160 |
Why?
|
TDP-43 Proteinopathies | 8 | 2021 | 105 | 2.050 |
Why?
|
Delay Discounting | 4 | 2023 | 26 | 2.050 |
Why?
|
Activities of Daily Living | 27 | 2014 | 507 | 2.040 |
Why?
|
DNA-Binding Proteins | 10 | 2019 | 263 | 1.980 |
Why?
|
Financial Management | 5 | 2020 | 25 | 1.980 |
Why?
|
Memory, Episodic | 10 | 2022 | 120 | 1.930 |
Why?
|
Educational Status | 20 | 2023 | 297 | 1.870 |
Why?
|
White Matter | 6 | 2020 | 150 | 1.830 |
Why?
|
Hippocampus | 10 | 2022 | 285 | 1.720 |
Why?
|
Neuropathology | 5 | 2022 | 81 | 1.600 |
Why?
|
Memory | 23 | 2018 | 323 | 1.560 |
Why?
|
Choice Behavior | 4 | 2019 | 56 | 1.560 |
Why?
|
Residence Characteristics | 15 | 2021 | 216 | 1.510 |
Why?
|
Economics | 4 | 2019 | 18 | 1.450 |
Why?
|
Magnetic Resonance Imaging | 18 | 2023 | 1247 | 1.450 |
Why?
|
Dementia, Vascular | 9 | 2018 | 44 | 1.440 |
Why?
|
Income | 8 | 2023 | 77 | 1.410 |
Why?
|
Blood Glucose | 2 | 2022 | 112 | 1.390 |
Why?
|
Disease Progression | 21 | 2021 | 812 | 1.380 |
Why?
|
Middle Aged | 78 | 2021 | 9960 | 1.380 |
Why?
|
Mortality | 10 | 2021 | 86 | 1.340 |
Why?
|
Hospitalization | 5 | 2019 | 319 | 1.320 |
Why?
|
Autopsy | 18 | 2021 | 338 | 1.310 |
Why?
|
Age Factors | 38 | 2021 | 853 | 1.290 |
Why?
|
Literacy | 2 | 2019 | 15 | 1.250 |
Why?
|
Amyloid beta-Peptides | 8 | 2023 | 302 | 1.240 |
Why?
|
Lewy Bodies | 12 | 2021 | 198 | 1.240 |
Why?
|
Motor Activity | 16 | 2015 | 372 | 1.220 |
Why?
|
Risk Factors | 40 | 2022 | 2465 | 1.210 |
Why?
|
Financing, Personal | 5 | 2020 | 19 | 1.180 |
Why?
|
Fraud | 4 | 2022 | 23 | 1.170 |
Why?
|
Neoplasms | 9 | 2009 | 257 | 1.140 |
Why?
|
Muscle Strength | 11 | 2012 | 129 | 1.090 |
Why?
|
Perception | 3 | 2019 | 83 | 1.080 |
Why?
|
Prospective Studies | 20 | 2022 | 1823 | 1.070 |
Why?
|
Goals | 3 | 2010 | 43 | 1.030 |
Why?
|
Quality of Life | 10 | 2015 | 677 | 1.010 |
Why?
|
Loneliness | 4 | 2020 | 55 | 1.010 |
Why?
|
Geriatric Assessment | 12 | 2015 | 221 | 1.010 |
Why?
|
Nerve Degeneration | 3 | 2014 | 55 | 0.980 |
Why?
|
Disability Evaluation | 9 | 2015 | 327 | 0.960 |
Why?
|
Neurofibrillary Tangles | 10 | 2019 | 189 | 0.950 |
Why?
|
Crime Victims | 2 | 2022 | 25 | 0.950 |
Why?
|
Proportional Hazards Models | 17 | 2019 | 346 | 0.940 |
Why?
|
Nervous System Diseases | 5 | 2019 | 150 | 0.940 |
Why?
|
Incidence | 30 | 2019 | 759 | 0.930 |
Why?
|
Medicare | 3 | 2023 | 123 | 0.920 |
Why?
|
Chicago | 14 | 2021 | 867 | 0.910 |
Why?
|
Government | 1 | 2023 | 3 | 0.900 |
Why?
|
Awareness | 5 | 2019 | 38 | 0.900 |
Why?
|
Sex Factors | 27 | 2019 | 497 | 0.870 |
Why?
|
Hypertension | 3 | 2022 | 272 | 0.860 |
Why?
|
Life Style | 4 | 2021 | 212 | 0.840 |
Why?
|
Memory, Short-Term | 4 | 2019 | 103 | 0.840 |
Why?
|
Arteriolosclerosis | 2 | 2023 | 74 | 0.830 |
Why?
|
Blood Pressure | 4 | 2022 | 252 | 0.830 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 970 | 0.830 |
Why?
|
Information Literacy | 3 | 2019 | 9 | 0.820 |
Why?
|
Atherosclerosis | 1 | 2023 | 75 | 0.800 |
Why?
|
Metacognition | 1 | 2021 | 3 | 0.800 |
Why?
|
Brain Mapping | 4 | 2018 | 199 | 0.790 |
Why?
|
Chronic Disease | 4 | 2017 | 508 | 0.780 |
Why?
|
Cerebral Arterial Diseases | 1 | 2021 | 8 | 0.780 |
Why?
|
Elder Abuse | 1 | 2022 | 34 | 0.780 |
Why?
|
Age of Onset | 2 | 2021 | 108 | 0.770 |
Why?
|
Reward | 2 | 2019 | 34 | 0.760 |
Why?
|
Follow-Up Studies | 24 | 2019 | 1859 | 0.730 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 79 | 0.730 |
Why?
|
Limbic Encephalitis | 1 | 2020 | 11 | 0.730 |
Why?
|
Plaque, Amyloid | 7 | 2019 | 146 | 0.720 |
Why?
|
Memory Disorders | 9 | 2019 | 177 | 0.700 |
Why?
|
Learning | 2 | 2018 | 80 | 0.700 |
Why?
|
Apolipoprotein E4 | 7 | 2019 | 233 | 0.700 |
Why?
|
Neurocognitive Disorders | 1 | 2019 | 19 | 0.680 |
Why?
|
Depression | 9 | 2021 | 472 | 0.670 |
Why?
|
Stroke | 1 | 2023 | 294 | 0.660 |
Why?
|
Risk | 11 | 2019 | 216 | 0.660 |
Why?
|
Prodromal Symptoms | 1 | 2019 | 19 | 0.650 |
Why?
|
Adult | 48 | 2022 | 8741 | 0.650 |
Why?
|
Cerebral Infarction | 8 | 2015 | 154 | 0.630 |
Why?
|
Agnosia | 2 | 2016 | 10 | 0.630 |
Why?
|
Mobility Limitation | 7 | 2019 | 97 | 0.620 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2018 | 52 | 0.600 |
Why?
|
Disabled Persons | 6 | 2019 | 129 | 0.570 |
Why?
|
United States | 15 | 2023 | 2344 | 0.560 |
Why?
|
Ambulatory Care | 1 | 2017 | 78 | 0.560 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 194 | 0.550 |
Why?
|
Postmortem Changes | 1 | 2016 | 34 | 0.540 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2018 | 201 | 0.530 |
Why?
|
Intention | 3 | 2010 | 26 | 0.530 |
Why?
|
Frail Elderly | 3 | 2014 | 51 | 0.530 |
Why?
|
Prostatic Hyperplasia | 3 | 2004 | 12 | 0.520 |
Why?
|
Temporal Lobe | 5 | 2020 | 109 | 0.520 |
Why?
|
Cognitive Reserve | 3 | 2021 | 38 | 0.510 |
Why?
|
Regression Analysis | 15 | 2015 | 298 | 0.490 |
Why?
|
Risk-Taking | 2 | 2011 | 32 | 0.480 |
Why?
|
Time Factors | 18 | 2020 | 1641 | 0.480 |
Why?
|
Europe | 14 | 2009 | 85 | 0.470 |
Why?
|
Frontal Lobe | 4 | 2018 | 85 | 0.470 |
Why?
|
Sclerosis | 6 | 2020 | 68 | 0.460 |
Why?
|
Mood Disorders | 2 | 2003 | 29 | 0.440 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2021 | 298 | 0.430 |
Why?
|
Surveys and Questionnaires | 11 | 2018 | 1187 | 0.430 |
Why?
|
Cause of Death | 5 | 2009 | 64 | 0.430 |
Why?
|
Genome-Wide Association Study | 5 | 2021 | 298 | 0.420 |
Why?
|
Social Class | 3 | 2022 | 65 | 0.420 |
Why?
|
Health Status | 7 | 2019 | 230 | 0.410 |
Why?
|
Cerebrovascular Disorders | 4 | 2021 | 139 | 0.410 |
Why?
|
Child, Preschool | 14 | 2013 | 654 | 0.400 |
Why?
|
Personality | 3 | 2021 | 67 | 0.400 |
Why?
|
Child | 17 | 2013 | 1377 | 0.390 |
Why?
|
Comorbidity | 8 | 2018 | 504 | 0.390 |
Why?
|
Statistics as Topic | 6 | 2017 | 114 | 0.380 |
Why?
|
Illinois | 5 | 2020 | 241 | 0.380 |
Why?
|
Risk Assessment | 7 | 2015 | 683 | 0.380 |
Why?
|
Urologic Diseases | 3 | 2003 | 5 | 0.370 |
Why?
|
Environmental Health | 1 | 2010 | 8 | 0.370 |
Why?
|
Mental Health | 4 | 2019 | 105 | 0.360 |
Why?
|
Adolescent | 18 | 2018 | 2332 | 0.360 |
Why?
|
Phobic Disorders | 1 | 2010 | 65 | 0.360 |
Why?
|
Models, Statistical | 5 | 2012 | 132 | 0.350 |
Why?
|
Brain Infarction | 4 | 2018 | 74 | 0.350 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 329 | 0.350 |
Why?
|
Death | 2 | 2020 | 48 | 0.340 |
Why?
|
Psychomotor Performance | 6 | 2019 | 220 | 0.340 |
Why?
|
Genetic Predisposition to Disease | 3 | 2018 | 433 | 0.340 |
Why?
|
Data Collection | 1 | 2010 | 108 | 0.340 |
Why?
|
Infant | 12 | 2009 | 542 | 0.340 |
Why?
|
Neurologic Examination | 4 | 2020 | 154 | 0.330 |
Why?
|
Linear Models | 7 | 2018 | 258 | 0.320 |
Why?
|
Diffusion Tensor Imaging | 2 | 2020 | 84 | 0.320 |
Why?
|
Multifactorial Inheritance | 3 | 2018 | 24 | 0.320 |
Why?
|
Brain Diseases | 3 | 2020 | 83 | 0.310 |
Why?
|
Lewy Body Disease | 5 | 2018 | 100 | 0.310 |
Why?
|
Frontotemporal Lobar Degeneration | 2 | 2019 | 28 | 0.310 |
Why?
|
Self Report | 5 | 2022 | 221 | 0.310 |
Why?
|
Prognosis | 6 | 2017 | 874 | 0.300 |
Why?
|
Parkinsonian Disorders | 2 | 2014 | 222 | 0.300 |
Why?
|
Severity of Illness Index | 11 | 2015 | 1126 | 0.300 |
Why?
|
Isometric Contraction | 1 | 2007 | 15 | 0.300 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2004 | 3 | 0.300 |
Why?
|
Brain Neoplasms | 3 | 1994 | 134 | 0.300 |
Why?
|
Executive Function | 2 | 2021 | 124 | 0.290 |
Why?
|
Urinary Retention | 2 | 2004 | 11 | 0.290 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 143 | 0.290 |
Why?
|
Lower Extremity | 1 | 2007 | 38 | 0.290 |
Why?
|
Infant, Newborn | 10 | 2009 | 618 | 0.280 |
Why?
|
Caregivers | 3 | 2005 | 144 | 0.280 |
Why?
|
Trust | 2 | 2019 | 16 | 0.280 |
Why?
|
Gait | 2 | 2007 | 406 | 0.280 |
Why?
|
Urination Disorders | 2 | 2003 | 7 | 0.280 |
Why?
|
Postural Balance | 1 | 2007 | 122 | 0.270 |
Why?
|
Sex Characteristics | 3 | 2022 | 135 | 0.260 |
Why?
|
Primary Prevention | 2 | 2019 | 39 | 0.260 |
Why?
|
Stress, Psychological | 4 | 2014 | 249 | 0.250 |
Why?
|
Atrophy | 3 | 2021 | 106 | 0.250 |
Why?
|
Self Efficacy | 1 | 2005 | 57 | 0.250 |
Why?
|
Cost of Illness | 1 | 2005 | 55 | 0.250 |
Why?
|
Sex Distribution | 6 | 2012 | 86 | 0.250 |
Why?
|
Reference Values | 3 | 2020 | 230 | 0.250 |
Why?
|
Interpersonal Relations | 3 | 2014 | 105 | 0.250 |
Why?
|
Age Distribution | 6 | 2007 | 95 | 0.240 |
Why?
|
Demography | 3 | 2018 | 78 | 0.240 |
Why?
|
Personal Satisfaction | 2 | 2016 | 48 | 0.240 |
Why?
|
Gray Matter | 2 | 2016 | 56 | 0.240 |
Why?
|
Finasteride | 1 | 2004 | 2 | 0.240 |
Why?
|
Cerebral Cortex | 3 | 2019 | 196 | 0.240 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2004 | 9 | 0.240 |
Why?
|
Neural Pathways | 3 | 2014 | 82 | 0.240 |
Why?
|
Longevity | 3 | 2013 | 32 | 0.230 |
Why?
|
Data Interpretation, Statistical | 2 | 2022 | 97 | 0.230 |
Why?
|
Cholinesterase Inhibitors | 1 | 2003 | 16 | 0.230 |
Why?
|
Government Agencies | 1 | 2023 | 4 | 0.230 |
Why?
|
Anxiety | 3 | 2019 | 157 | 0.230 |
Why?
|
Mouth Neoplasms | 5 | 1997 | 16 | 0.230 |
Why?
|
Problem Solving | 1 | 2004 | 47 | 0.230 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 147 | 0.230 |
Why?
|
Apolipoproteins E | 3 | 2013 | 235 | 0.220 |
Why?
|
Anxiety Disorders | 2 | 2016 | 169 | 0.220 |
Why?
|
Individuality | 2 | 2021 | 22 | 0.220 |
Why?
|
Erectile Dysfunction | 1 | 2003 | 48 | 0.220 |
Why?
|
Anisotropy | 2 | 2020 | 60 | 0.220 |
Why?
|
Infarction | 1 | 2023 | 25 | 0.210 |
Why?
|
Motivation | 1 | 2003 | 101 | 0.210 |
Why?
|
Models, Theoretical | 1 | 2003 | 94 | 0.210 |
Why?
|
Survival Rate | 3 | 2012 | 376 | 0.210 |
Why?
|
Mental Recall | 2 | 2020 | 74 | 0.210 |
Why?
|
Reaction Time | 2 | 2020 | 124 | 0.210 |
Why?
|
Mental Status and Dementia Tests | 2 | 2019 | 81 | 0.210 |
Why?
|
Prefrontal Cortex | 2 | 2014 | 152 | 0.210 |
Why?
|
Motor Skills | 2 | 2013 | 62 | 0.200 |
Why?
|
Biomarkers | 3 | 2023 | 704 | 0.200 |
Why?
|
Predictive Value of Tests | 7 | 2008 | 532 | 0.200 |
Why?
|
Adenocarcinoma | 4 | 2001 | 194 | 0.190 |
Why?
|
Healthy Volunteers | 1 | 2021 | 46 | 0.190 |
Why?
|
Memory and Learning Tests | 1 | 2020 | 7 | 0.190 |
Why?
|
Serial Learning | 1 | 2020 | 8 | 0.190 |
Why?
|
Mental Disorders | 2 | 2018 | 142 | 0.190 |
Why?
|
Psychometrics | 3 | 2014 | 264 | 0.180 |
Why?
|
Healthy Aging | 1 | 2020 | 13 | 0.180 |
Why?
|
Neurons | 2 | 2013 | 380 | 0.180 |
Why?
|
Musculoskeletal Diseases | 2 | 2010 | 41 | 0.180 |
Why?
|
Antihypertensive Agents | 2 | 2020 | 85 | 0.180 |
Why?
|
Gait Disorders, Neurologic | 1 | 2002 | 144 | 0.170 |
Why?
|
Space Perception | 1 | 2019 | 28 | 0.170 |
Why?
|
Self Concept | 1 | 2020 | 46 | 0.170 |
Why?
|
Frailty | 1 | 2020 | 39 | 0.170 |
Why?
|
Korea | 3 | 2003 | 10 | 0.170 |
Why?
|
Depressive Disorder, Major | 2 | 2016 | 106 | 0.170 |
Why?
|
Uterine Cervical Neoplasms | 2 | 1998 | 51 | 0.170 |
Why?
|
Neuronal Plasticity | 1 | 2019 | 43 | 0.170 |
Why?
|
Emergencies | 1 | 2019 | 39 | 0.160 |
Why?
|
Computer Graphics | 1 | 1998 | 5 | 0.160 |
Why?
|
Renal Dialysis | 1 | 1999 | 110 | 0.160 |
Why?
|
Kidney | 2 | 2010 | 176 | 0.160 |
Why?
|
Smoking | 6 | 2001 | 194 | 0.160 |
Why?
|
Lung | 2 | 2009 | 158 | 0.150 |
Why?
|
Neurodevelopmental Disorders | 1 | 2018 | 20 | 0.150 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2018 | 23 | 0.150 |
Why?
|
Mental Status Schedule | 3 | 2007 | 114 | 0.150 |
Why?
|
Muscle Weakness | 2 | 2008 | 34 | 0.150 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 282 | 0.150 |
Why?
|
Registries | 5 | 2003 | 191 | 0.150 |
Why?
|
Alcohol Drinking | 3 | 1998 | 77 | 0.150 |
Why?
|
Kidney Failure, Chronic | 1 | 1999 | 158 | 0.150 |
Why?
|
Salivary Gland Neoplasms | 1 | 1997 | 7 | 0.150 |
Why?
|
Pain | 2 | 2010 | 396 | 0.140 |
Why?
|
Brain Stem | 2 | 2016 | 25 | 0.140 |
Why?
|
Social Behavior | 2 | 2011 | 99 | 0.140 |
Why?
|
Gene Expression | 1 | 2017 | 231 | 0.140 |
Why?
|
Lung Neoplasms | 5 | 2003 | 636 | 0.140 |
Why?
|
RNA, Messenger | 1 | 2017 | 323 | 0.140 |
Why?
|
Deafness | 1 | 1997 | 16 | 0.140 |
Why?
|
Personality Development | 1 | 2016 | 6 | 0.140 |
Why?
|
DNA Methylation | 1 | 2017 | 127 | 0.140 |
Why?
|
Cochlear Implantation | 1 | 1997 | 22 | 0.140 |
Why?
|
Locus Coeruleus | 2 | 2013 | 23 | 0.140 |
Why?
|
Neurotic Disorders | 2 | 2018 | 19 | 0.140 |
Why?
|
Thyroid Neoplasms | 1 | 1996 | 38 | 0.130 |
Why?
|
Affect | 1 | 2016 | 65 | 0.130 |
Why?
|
Fetus | 1 | 2016 | 56 | 0.130 |
Why?
|
Psychological Tests | 2 | 2015 | 52 | 0.130 |
Why?
|
Intelligence | 1 | 2016 | 25 | 0.130 |
Why?
|
Logistic Models | 5 | 2016 | 410 | 0.130 |
Why?
|
Comprehension | 1 | 2016 | 28 | 0.130 |
Why?
|
Brain Chemistry | 1 | 2016 | 46 | 0.130 |
Why?
|
Scotland | 6 | 2007 | 7 | 0.130 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2016 | 40 | 0.130 |
Why?
|
Psychiatric Status Rating Scales | 5 | 2016 | 351 | 0.130 |
Why?
|
Vascular Diseases | 2 | 2013 | 53 | 0.130 |
Why?
|
tau Proteins | 4 | 2023 | 213 | 0.130 |
Why?
|
Organ Size | 1 | 2015 | 107 | 0.130 |
Why?
|
Breast Neoplasms | 4 | 2000 | 352 | 0.120 |
Why?
|
Muscle, Skeletal | 2 | 2008 | 355 | 0.120 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 55 | 0.120 |
Why?
|
Case-Control Studies | 7 | 2001 | 641 | 0.120 |
Why?
|
Multilingualism | 1 | 2014 | 11 | 0.120 |
Why?
|
Harm Reduction | 1 | 2014 | 5 | 0.120 |
Why?
|
Gyrus Cinguli | 1 | 2014 | 22 | 0.120 |
Why?
|
Music | 1 | 2014 | 19 | 0.120 |
Why?
|
Poverty | 1 | 2015 | 97 | 0.120 |
Why?
|
Anticarcinogenic Agents | 2 | 2000 | 16 | 0.120 |
Why?
|
Language | 2 | 2014 | 78 | 0.120 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 1994 | 24 | 0.110 |
Why?
|
Medicare Part D | 1 | 2013 | 7 | 0.110 |
Why?
|
Mesencephalon | 1 | 2013 | 47 | 0.110 |
Why?
|
Cerebellum | 1 | 2013 | 52 | 0.110 |
Why?
|
France | 3 | 2003 | 36 | 0.110 |
Why?
|
Retirement | 2 | 2011 | 11 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2016 | 221 | 0.110 |
Why?
|
Causality | 3 | 2012 | 52 | 0.110 |
Why?
|
Psychomotor Disorders | 1 | 2013 | 10 | 0.110 |
Why?
|
Neuroticism | 3 | 2021 | 34 | 0.110 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 337 | 0.110 |
Why?
|
Retinoids | 1 | 1992 | 5 | 0.110 |
Why?
|
Leukoplakia, Oral | 1 | 1992 | 4 | 0.110 |
Why?
|
Epidemiologic Research Design | 1 | 2012 | 16 | 0.110 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2012 | 26 | 0.110 |
Why?
|
Gallbladder Neoplasms | 1 | 1992 | 5 | 0.100 |
Why?
|
Diagnosis, Differential | 2 | 2004 | 398 | 0.100 |
Why?
|
Child Abuse | 1 | 2012 | 36 | 0.100 |
Why?
|
Terminally Ill | 1 | 2012 | 5 | 0.100 |
Why?
|
Models, Psychological | 1 | 2012 | 67 | 0.100 |
Why?
|
Health Surveys | 2 | 2007 | 96 | 0.100 |
Why?
|
Urban Population | 2 | 2010 | 143 | 0.100 |
Why?
|
Emotions | 1 | 2012 | 90 | 0.100 |
Why?
|
Respiratory Muscles | 2 | 2008 | 18 | 0.100 |
Why?
|
Alleles | 4 | 2015 | 216 | 0.100 |
Why?
|
England | 2 | 2003 | 14 | 0.100 |
Why?
|
Social Environment | 1 | 2011 | 81 | 0.090 |
Why?
|
Movement Disorders | 1 | 2012 | 148 | 0.090 |
Why?
|
Odorants | 2 | 2009 | 23 | 0.090 |
Why?
|
Social Participation | 1 | 2011 | 11 | 0.090 |
Why?
|
Connecticut | 5 | 1997 | 6 | 0.090 |
Why?
|
Leg | 2 | 2008 | 49 | 0.090 |
Why?
|
Motor Skills Disorders | 1 | 2010 | 18 | 0.090 |
Why?
|
Knowledge | 1 | 2010 | 19 | 0.090 |
Why?
|
Patient Satisfaction | 2 | 2003 | 297 | 0.090 |
Why?
|
Potassium | 2 | 2010 | 68 | 0.090 |
Why?
|
Beer | 1 | 1990 | 1 | 0.090 |
Why?
|
Alcoholic Beverages | 1 | 1990 | 2 | 0.090 |
Why?
|
Odds Ratio | 5 | 2007 | 286 | 0.090 |
Why?
|
Housing for the Elderly | 1 | 2010 | 7 | 0.090 |
Why?
|
Physical Fitness | 2 | 2008 | 59 | 0.090 |
Why?
|
Neuroimaging | 2 | 2022 | 138 | 0.090 |
Why?
|
Muscle Strength Dynamometer | 1 | 2009 | 16 | 0.090 |
Why?
|
Attitude to Health | 2 | 2003 | 98 | 0.080 |
Why?
|
Social Adjustment | 1 | 2009 | 29 | 0.080 |
Why?
|
Prevalence | 3 | 2012 | 494 | 0.080 |
Why?
|
Body Mass Index | 4 | 2012 | 425 | 0.080 |
Why?
|
Confidence Intervals | 3 | 2012 | 96 | 0.080 |
Why?
|
Pancreatic Neoplasms | 1 | 1990 | 151 | 0.080 |
Why?
|
Olfaction Disorders | 1 | 2009 | 53 | 0.080 |
Why?
|
Community Health Services | 1 | 2009 | 31 | 0.080 |
Why?
|
Depressive Disorder | 3 | 2007 | 191 | 0.080 |
Why?
|
Epidemiologic Studies | 2 | 2005 | 23 | 0.080 |
Why?
|
Forecasting | 2 | 2009 | 117 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2009 | 97 | 0.070 |
Why?
|
Exercise | 4 | 2012 | 474 | 0.070 |
Why?
|
Hand Strength | 1 | 2007 | 60 | 0.070 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2007 | 36 | 0.070 |
Why?
|
Epidemiology | 1 | 2007 | 5 | 0.070 |
Why?
|
Observation | 1 | 2007 | 16 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2001 | 180 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2014 | 802 | 0.070 |
Why?
|
Laryngeal Neoplasms | 1 | 1987 | 29 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2007 | 103 | 0.070 |
Why?
|
Netherlands | 2 | 2003 | 10 | 0.070 |
Why?
|
United Kingdom | 2 | 2016 | 51 | 0.070 |
Why?
|
Myocardial Infarction | 1 | 2007 | 175 | 0.070 |
Why?
|
Exercise Therapy | 1 | 2007 | 112 | 0.070 |
Why?
|
Cerebral Arteries | 1 | 2005 | 31 | 0.070 |
Why?
|
Genetic Loci | 2 | 2018 | 61 | 0.070 |
Why?
|
Multicenter Studies as Topic | 2 | 2003 | 77 | 0.070 |
Why?
|
Interview, Psychological | 1 | 2005 | 36 | 0.060 |
Why?
|
Retrospective Studies | 4 | 2019 | 3325 | 0.060 |
Why?
|
Home Nursing | 1 | 2005 | 19 | 0.060 |
Why?
|
Sertraline | 2 | 2002 | 23 | 0.060 |
Why?
|
Social Support | 2 | 2020 | 186 | 0.060 |
Why?
|
Models, Biological | 1 | 1987 | 347 | 0.060 |
Why?
|
Italy | 4 | 1998 | 15 | 0.060 |
Why?
|
Acute Disease | 2 | 2004 | 225 | 0.060 |
Why?
|
New South Wales | 2 | 1994 | 4 | 0.060 |
Why?
|
Libido | 1 | 2003 | 7 | 0.060 |
Why?
|
Ejaculation | 1 | 2003 | 8 | 0.060 |
Why?
|
Young Adult | 3 | 2018 | 1966 | 0.060 |
Why?
|
Heterozygote | 2 | 2015 | 103 | 0.060 |
Why?
|
Australia | 3 | 1999 | 46 | 0.060 |
Why?
|
Vital Statistics | 1 | 2003 | 1 | 0.060 |
Why?
|
Azasteroids | 1 | 2003 | 2 | 0.060 |
Why?
|
Health Care Surveys | 1 | 2003 | 67 | 0.060 |
Why?
|
Genotype | 2 | 2015 | 399 | 0.050 |
Why?
|
Carcinoma, Small Cell | 2 | 2001 | 71 | 0.050 |
Why?
|
Cardiovascular Diseases | 1 | 2007 | 411 | 0.050 |
Why?
|
Observer Variation | 1 | 2003 | 119 | 0.050 |
Why?
|
Survival Analysis | 1 | 2003 | 310 | 0.050 |
Why?
|
Program Evaluation | 1 | 2003 | 135 | 0.050 |
Why?
|
Mendelian Randomization Analysis | 1 | 2021 | 7 | 0.050 |
Why?
|
Computer Simulation | 1 | 2003 | 218 | 0.050 |
Why?
|
Epidemiologic Methods | 2 | 2015 | 20 | 0.050 |
Why?
|
Mitochondrial Proteins | 1 | 2021 | 21 | 0.050 |
Why?
|
Health Behavior | 2 | 2014 | 159 | 0.050 |
Why?
|
Brazil | 1 | 2021 | 37 | 0.050 |
Why?
|
Antidepressive Agents | 1 | 2002 | 103 | 0.050 |
Why?
|
beta-Lactamases | 1 | 2021 | 72 | 0.050 |
Why?
|
Spouses | 1 | 2000 | 26 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2021 | 178 | 0.050 |
Why?
|
Switzerland | 2 | 1990 | 9 | 0.040 |
Why?
|
Machine Learning | 1 | 2020 | 54 | 0.040 |
Why?
|
Selenium | 1 | 2000 | 7 | 0.040 |
Why?
|
Nails | 1 | 2000 | 2 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 558 | 0.040 |
Why?
|
New Zealand | 1 | 1999 | 13 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2000 | 67 | 0.040 |
Why?
|
Frontotemporal Dementia | 1 | 2019 | 14 | 0.040 |
Why?
|
Sleep Wake Disorders | 1 | 2000 | 148 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2000 | 110 | 0.040 |
Why?
|
Women's Health | 1 | 2001 | 247 | 0.040 |
Why?
|
Wales | 1 | 1998 | 4 | 0.040 |
Why?
|
Spain | 1 | 1998 | 20 | 0.040 |
Why?
|
Proteomics | 1 | 2019 | 93 | 0.040 |
Why?
|
Poisson Distribution | 1 | 1998 | 25 | 0.040 |
Why?
|
Testicular Neoplasms | 1 | 1998 | 23 | 0.040 |
Why?
|
Japan | 4 | 2001 | 11 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2019 | 411 | 0.040 |
Why?
|
Algorithms | 1 | 2021 | 400 | 0.040 |
Why?
|
Religious Personnel | 1 | 2018 | 11 | 0.040 |
Why?
|
Protein-Arginine Deiminases | 1 | 2017 | 11 | 0.040 |
Why?
|
alpha-Macroglobulins | 1 | 2017 | 12 | 0.040 |
Why?
|
Sequence Analysis, RNA | 1 | 2017 | 43 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2017 | 38 | 0.040 |
Why?
|
Gingival Neoplasms | 1 | 1997 | 1 | 0.040 |
Why?
|
Feeding Behavior | 1 | 1998 | 99 | 0.040 |
Why?
|
Sampling Studies | 3 | 2002 | 29 | 0.040 |
Why?
|
Czechoslovakia | 2 | 2001 | 2 | 0.040 |
Why?
|
Adenocarcinoma, Follicular | 1 | 1996 | 5 | 0.030 |
Why?
|
Carcinoma, Papillary | 1 | 1996 | 20 | 0.030 |
Why?
|
Time | 1 | 1996 | 17 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2016 | 40 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 6 | 0.030 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1996 | 16 | 0.030 |
Why?
|
Computational Biology | 1 | 2016 | 24 | 0.030 |
Why?
|
Radiotherapy | 1 | 1996 | 53 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2016 | 19 | 0.030 |
Why?
|
Vulnerable Populations | 1 | 2016 | 24 | 0.030 |
Why?
|
ROC Curve | 1 | 2016 | 140 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2016 | 39 | 0.030 |
Why?
|
SEER Program | 1 | 1996 | 38 | 0.030 |
Why?
|
Diet | 2 | 2000 | 172 | 0.030 |
Why?
|
Speech Perception | 1 | 1997 | 48 | 0.030 |
Why?
|
Schizophrenia | 1 | 2016 | 70 | 0.030 |
Why?
|
Urology | 1 | 1995 | 16 | 0.030 |
Why?
|
Family Practice | 1 | 1995 | 20 | 0.030 |
Why?
|
Bipolar Disorder | 1 | 2016 | 105 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2016 | 78 | 0.030 |
Why?
|
Markov Chains | 1 | 2015 | 29 | 0.030 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 96 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2015 | 86 | 0.030 |
Why?
|
Phenotype | 1 | 2016 | 362 | 0.030 |
Why?
|
Life Change Events | 1 | 2014 | 36 | 0.030 |
Why?
|
Canada | 2 | 1994 | 56 | 0.030 |
Why?
|
Empathy | 1 | 2014 | 36 | 0.030 |
Why?
|
Carcinoma | 1 | 1994 | 59 | 0.030 |
Why?
|
Raphe Nuclei | 1 | 2013 | 8 | 0.030 |
Why?
|
Ventral Tegmental Area | 1 | 2013 | 12 | 0.030 |
Why?
|
Lip Neoplasms | 1 | 1993 | 2 | 0.030 |
Why?
|
World Health Organization | 3 | 2003 | 19 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2014 | 81 | 0.030 |
Why?
|
Fathers | 1 | 1994 | 22 | 0.030 |
Why?
|
Cell Count | 1 | 2013 | 97 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2013 | 44 | 0.030 |
Why?
|
Endophenotypes | 1 | 2013 | 12 | 0.030 |
Why?
|
Religion | 1 | 2013 | 40 | 0.030 |
Why?
|
Isotretinoin | 1 | 1992 | 8 | 0.030 |
Why?
|
Vitamin A | 1 | 1992 | 6 | 0.030 |
Why?
|
Carotenoids | 1 | 1992 | 8 | 0.030 |
Why?
|
Poland | 1 | 1992 | 6 | 0.030 |
Why?
|
Coffee | 1 | 1992 | 4 | 0.030 |
Why?
|
Substantia Nigra | 1 | 2013 | 149 | 0.030 |
Why?
|
Neocortex | 1 | 2012 | 34 | 0.030 |
Why?
|
Pregnancy | 1 | 1994 | 388 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1992 | 42 | 0.030 |
Why?
|
Respiratory Tract Neoplasms | 1 | 1992 | 1 | 0.030 |
Why?
|
Esophageal Neoplasms | 1 | 1992 | 46 | 0.030 |
Why?
|
Actigraphy | 1 | 2012 | 98 | 0.030 |
Why?
|
Energy Intake | 1 | 1992 | 66 | 0.030 |
Why?
|
Games, Experimental | 1 | 2011 | 9 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2012 | 53 | 0.020 |
Why?
|
Probability | 1 | 2011 | 93 | 0.020 |
Why?
|
Parents | 1 | 2012 | 106 | 0.020 |
Why?
|
Nerve Net | 1 | 2011 | 54 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 1992 | 67 | 0.020 |
Why?
|
Oxygen | 1 | 2011 | 86 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 1992 | 51 | 0.020 |
Why?
|
Bulgaria | 1 | 1990 | 1 | 0.020 |
Why?
|
Germany, West | 1 | 1990 | 1 | 0.020 |
Why?
|
Yugoslavia | 1 | 1990 | 1 | 0.020 |
Why?
|
Denmark | 1 | 1990 | 12 | 0.020 |
Why?
|
Visual Perception | 1 | 2011 | 50 | 0.020 |
Why?
|
Research Design | 1 | 2012 | 214 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 1992 | 106 | 0.020 |
Why?
|
Wine | 1 | 1990 | 8 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 137 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1989 | 19 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2009 | 33 | 0.020 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 1989 | 1 | 0.020 |
Why?
|
Microcirculation | 1 | 2009 | 39 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2003 | 3561 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 59 | 0.020 |
Why?
|
Animals | 1 | 1998 | 4634 | 0.020 |
Why?
|
Extremities | 1 | 2008 | 33 | 0.020 |
Why?
|
Tissue Donors | 1 | 2009 | 73 | 0.020 |
Why?
|
Catholicism | 1 | 2007 | 21 | 0.020 |
Why?
|
Cardiovascular Agents | 1 | 2007 | 29 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 2007 | 55 | 0.020 |
Why?
|
Models, Neurological | 1 | 2007 | 32 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2007 | 32 | 0.020 |
Why?
|
Clergy | 1 | 2007 | 90 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2007 | 140 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2007 | 332 | 0.020 |
Why?
|
Porphyrias | 1 | 1985 | 1 | 0.020 |
Why?
|
Autonomic Nervous System Diseases | 1 | 1985 | 28 | 0.020 |
Why?
|
Cohort Effect | 2 | 1994 | 2 | 0.020 |
Why?
|
Dutasteride | 1 | 2003 | 2 | 0.010 |
Why?
|
Death Certificates | 1 | 2003 | 1 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2003 | 120 | 0.010 |
Why?
|
Citalopram | 1 | 2002 | 7 | 0.010 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2002 | 28 | 0.010 |
Why?
|
Outpatients | 1 | 2002 | 54 | 0.010 |
Why?
|
Slovakia | 1 | 2001 | 1 | 0.010 |
Why?
|
Bendroflumethiazide | 1 | 1980 | 1 | 0.010 |
Why?
|
Metolazone | 1 | 1980 | 2 | 0.010 |
Why?
|
Diuretics | 1 | 1980 | 17 | 0.010 |
Why?
|
Hawaii | 1 | 2000 | 3 | 0.010 |
Why?
|
Neutron Activation Analysis | 1 | 2000 | 1 | 0.010 |
Why?
|
Toes | 1 | 2000 | 5 | 0.010 |
Why?
|
Population Surveillance | 1 | 2000 | 118 | 0.010 |
Why?
|
beta Carotene | 1 | 1998 | 7 | 0.010 |
Why?
|
Biomarkers, Tumor | 1 | 2000 | 198 | 0.010 |
Why?
|
Vitamin E | 1 | 1998 | 27 | 0.010 |
Why?
|
Postmenopause | 1 | 1998 | 61 | 0.010 |
Why?
|
Antioxidants | 1 | 1998 | 61 | 0.010 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 1994 | 3 | 0.010 |
Why?
|
North America | 1 | 1994 | 39 | 0.010 |
Why?
|
Public Health | 1 | 1994 | 62 | 0.010 |
Why?
|
Tongue Neoplasms | 1 | 1992 | 16 | 0.010 |
Why?
|
Pleural Neoplasms | 1 | 1992 | 9 | 0.010 |
Why?
|
Parasympathetic Nervous System | 1 | 1985 | 2 | 0.000 |
Why?
|
Valsalva Maneuver | 1 | 1985 | 4 | 0.000 |
Why?
|
Sympathetic Nervous System | 1 | 1985 | 9 | 0.000 |
Why?
|
Respiration | 1 | 1985 | 35 | 0.000 |
Why?
|
Posture | 1 | 1985 | 79 | 0.000 |
Why?
|
Muscle Contraction | 1 | 1985 | 83 | 0.000 |
Why?
|
Heart Rate | 1 | 1985 | 152 | 0.000 |
Why?
|